Author:
Peter Samuel C.,Murphy James G.,Witkiewitz Katie,Hand Sarah B.,Thomas Fridtjof,Johnson Karen Chandler,Cowan Ronald,Harris Matt,Derefinko Karen J.
Abstract
Abstract
Background
Buprenorphine-naloxone is a medication shown to improve outcomes for individuals seeking treatment for opioid use disorder (OUD); however, outcomes are limited by low medication adherence rates. This is especially true during the early stages of treatment.
Methods
The present study proposes to utilize a sequential multiple assignment randomized trial design to compare two psychological interventions targeting buprenorphine-naloxone adherence: (1) contingency management (CM) and (2) brief motivational interviewing plus substance-free activities session plus mindfulness (BSM). Participants will be N = 280 adults who present to a university-based addictions clinic seeking treatment for OUD. Participants will be randomized to condition to receive 4 sessions of their assigned intervention (CM or BSM). Participants who are adherent, defined as attending physician appointments and having buprenorphine present in urine toxicology, will enter maintenance intervention for an additional 6 months. Those who are not adherent will be re-randomized to receive either the other intervention or both interventions. Follow-up will occur at 8 months post-randomization.
Conclusions
This novel design will examine the benefit of sequential treatment decisions following non-adherence. The primary outcome of this study is buprenorphine-naloxone medication adherence, as assessed by physician visit attendance and presence of buprenorphine in urine. Results will elicit the relative efficacy of CM and BSM compared to one another and whether keeping the initial treatment approach when adding the alternative approach for initially non-adherent individuals is beneficial.
Trial registration
ClinicalTrials.gov NCT04080180
Funder
National Center for Complementary and Integrative Health
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Medicine (miscellaneous)
Reference83 articles.
1. Ling W, Amass L, Shoptaw S, et al. A multi-center randomized trial of buprenorphine–naloxone versus clonidine for opioid, detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction. 2005;100(8):1090–100.
2. Fiellin DA, Moore BA, Sullivan LE, et al. Long-term treatment with buprenorphine/naloxone in primary care: Results at 2–5 years. Am J Addict. 2008;17(2):116–20.
3. Canadian Agency for Drugs and Technologies in Health. Buprenorphine/naloxone versus methadone for the treatment of opioid dependence: a review of Comparative Clinical Effectiveness, Cost-Effectiveness and Guidelines. 2016; https://www.ncbi.nlm.nih.gov/books/NBK385172/. Accessed 30 Jan 2019.
4. Curcio F, Franco T, Topa M, Baldassarre C. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey. Eur Rev Med Pharmacol Sci. 2011;15(8):871–4.
5. Fiellin DA, Pantalon MV, Chawarski MC, et al. Counseling plus buprenorphine–naloxone maintenance therapy for opioid dependence. N Engl J Med. 2006;355(4):365–74.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献